What do systematic reviews say?

Nebulized budesonide vs viscous budesonide

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Nebulized budesonide vs viscous budesonide

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Very low

Corticosteroids vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 269 participants
  Very low

Nebulized budesonide vs viscous budesonide

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nebulized budesonide vs viscous budesonide

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Very low

Viaskin milk patch vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Viaskin milk patch vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 9 participants
  Low

Viaskin milk patch vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Viaskin milk patch vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 9 participants
  Low

Viaskin milk patch vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Viaskin milk patch vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Low

Viaskin milk patch vs placebo

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.12 [0.05, 23.99]
  1 study · 20 participants
  Low

Leukotriene receptor antagonist vs placebo

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.68 [0.66, 4.28]
  1 study · 41 participants
  Very low

Vitamin D vs placebo/no treatment

It is very uncertain whether vitamin D (all doses) changes clinical response at end of study (4 weeks) compared with placebo/no treatment (very low certainty).

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 4 [1.51, 10.57]
  1 study · 60 participants
  Very low

Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day)

The review found no eligible studies for this question.

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day)

The review found no eligible studies for this question.

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day)

It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 3.09 [0.13, 73.17]
  4 studies · 233 participants
  Very low

Vitamin D vs placebo/no treatment

Vitamin D (all doses) may leads to lower clinical relapse at end of study (26–52) weeks compared with placebo/no treatment (low certainty).

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 0.57 [0.34, 0.96]
  3 studies · 310 participants
  Low

Vitamin D vs placebo/no treatment

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 243 participants
  Very low

Vitamin D vs placebo/no treatment

It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.97 [0.18, 21.27]
  12 studies · 1251 participants
  Very low